Nyxoah SA Earnings Reports

Nyxoah recorded €1.1 million in revenue for Q1 2025, slightly below last year. The company's operating loss widened to €20.6 million as it ramped up expenses in preparation for the U.S. commercialization of its Genio® system. With the FDA approval process nearing completion, Nyxoah maintained a strong cash position to support its strategic objectives.

Nyxoah's Q4 2024 revenue reached €1.3 million, with a gross margin of 73%. However, increased research and development expenses contributed to a higher operating loss of €18.3 million. The company is preparing for its U.S. commercial launch in March 2025, following anticipated FDA approval.